Dr. Patrick Soon-Shiong CEO of NantWorks and founder of Cancer Moonshot 2020. The Cancer MoonShot 2020 Program is one of the most comprehensive cancer collaborative initiatives launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational moonshot to develop an effective vaccine-based immunotherapy to combat cancer by 2020.

Merriman Financial Entreprene​ur Platform

Responsibilities included providing strategic direction to upper management including Go/No-Go decisions, strategic recommendations, M&A options, Unbiased Sharpe portfolio, Clinical Development Plans and Hedge Risk Strategies. Additional responsibilities include developing relationships with key opinion leaders in clinical, medical and academia. Develop and maintain ownership for commercial and scientific expertise of key therapeutic areas. Spearhead investigations of therapeutic areas new to ImClone and develop recommendations for market entry. Build the vision for what markets might look like five to ten years in the future, including how changes in diagnostics, clinical guidelines, and new therapies, will shape the landscape. Review market research and facilitate the group's ability to project future marketplace dynamics and future product or company licensing opportunities. Develop new tools for group to use in assessing markets and forecasting new opportunities. Identify alternative strategies, quantifying risks, and forecasting product sales and profits under various scenarios. Present strategic options and recommendations to licensing project team and senior management.

Strategy Consulting Pharmaceutical and Medical Practice (US and EU) Wyeth ­ introduced Real Options Analysis to strategically align $1.5B R&D portfolio with capital budgeting and enhanced quality/timeliness of decision-making processes. Johnson & Johnson/Janssen Pharmaceutical in Belgium ­ Developed global $3B R&D capabilities leading post-merger integration process building a Global R&D Pharmaceutical Group. Developed $1M e-Detailing capabilities for Lipitor in partnership with Quest Diagnostics and Pfizer.

Oncology and Cox-II Responsible for Scaling Up R&D Processes from Bench to Clinical Development including; NDA applications, Defining Drug Substance Purity Profile, setting Key Performance Indicators, transferring technologies, evaluating and implementing new technologies, ensuring process safety, process efficiency and selecting key chemical intermediates of reaction. Responsibilities also included coordinating chemical & pharmaceutical development priorities with the Medical and Clinical teams.